Definition
The presence of phenotypic, genotypic, and epigenetic variation among cells within a single tumor.
The genetic, epigenetic, and phenotypic variation among cancer cells within a single tumor.
Related Claims
- Primary glioblastomas contain inherent variability in oncogenic signaling expression
- Established glioblastoma subtype classifiers are variably expressed within tumors
- Proliferation and immune response programs vary across individual glioblastoma cells
- Hypoxia-related transcriptional programs are variably expressed in glioblastoma cells
- Bulk sequencing masks intratumoral copy number heterogeneity
Synthesis
Intratumoral heterogeneity, defined as the genetic, epigenetic, and phenotypic variation among cancer cells within a single tumor, is now established as a fundamental property of malignancies, particularly glioblastoma, where single-cell RNA sequencing has revealed extensive cell-to-cell variability in gene expression patterns, oncogenic signaling programs, and molecular subtype classifiers. Mechanistically, this heterogeneity arises through subclonal evolution as cells accumulate distinct genetic alterations including driver mutations and copy number variations, with different cellular populations experiencing or responding differently to microenvironmental pressures such as hypoxia, resulting in variable expression of adaptive transcriptional programs related to proliferation, immune response, and stress responses. The clinical implications of this heterogeneity remain contested, as traditional bulk sequencing approaches mask cell-to-cell variability and generate population-level molecular signatures whose validity is increasingly questioned by single-cell analyses, though resolving subclonal architecture may improve patient stratification and clinical trial design in precision medicine approaches. A key unresolved question is whether the observed transcriptional heterogeneity represents stable cellular states or transient phenotypic plasticity, with implications for whether tumors should be targeted based on dominant clones or require multi-pronged therapeutic strategies.